{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Urothelial+Cell+Carcinoma&page=3", "query": { "condition": "Locally Advanced or Metastatic Urothelial Cell Carcinoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 80, "total_pages": 8, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Urothelial+Cell+Carcinoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Locally+Advanced+or+Metastatic+Urothelial+Cell+Carcinoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T15:01:29.854Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03047213", "title": "Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Metastatic Transitional Cell Carcinoma", "Metastatic Urothelial Carcinoma", "Recurrent Bladder Carcinoma", "Stage III Bladder Urothelial Carcinoma AJCC v6 and v7", "Stage IV Bladder Urothelial Carcinoma AJCC v7" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2017-08-24", "completion_date": "2026-11-12", "has_results": true, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 20, "location_summary": "Los Angeles, California • Pasadena, California • Sacramento, California + 12 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03047213" }, { "nct_id": "NCT04887831", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients With Advanced/Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma", "Bladder Cancer", "Myelosuppression Adult", "Chemotherapy-induced Neutropenia", "Metastatic Bladder Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 92, "start_date": "2021-06-04", "completion_date": "2024-03-01", "has_results": true, "last_update_posted_date": "2025-09-08", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 13, "location_summary": "Los Angeles, California • Whittier, California • Littleton, Colorado + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Whittier", "state": "California" }, { "city": "Littleton", "state": "Colorado" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Pensacola", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04887831" }, { "nct_id": "NCT04879329", "title": "A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "disitamab vedotin", "type": "DRUG" }, { "name": "pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen, a wholly owned subsidiary of Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 372, "start_date": "2022-05-03", "completion_date": "2029-04-14", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 158, "location_summary": "Gilbert, Arizona • Anaheim, California • Arcadia, California + 96 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Arcadia", "state": "California" }, { "city": "Baldwin Park", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879329" }, { "nct_id": "NCT07218003", "title": "A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Small Cell Lung Cancer", "Cervical Cancer", "Head and Neck Squamous Cell Cancer", "Triple Negative Breast Cancer (TNBC)", "Urothelial Carcinoma Bladder", "Gastroesophageal Junction (GEJ) Adenocarcinoma", "Esophageal Squamous Cell Cancer", "Gastric Cancer", "Cancer", "Solid Tumors (Phase 1)" ], "interventions": [ { "name": "RNDO-564", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rondo Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 149, "start_date": "2025-11-17", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-06-11", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 11, "location_summary": "San Francisco, California • New Haven, Connecticut • Grand Rapids, Michigan + 8 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "New York", "state": "New York" }, { "city": "Huntersville", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07218003" }, { "nct_id": "NCT04136808", "title": "An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma", "overall_status": "APPROVED_FOR_MARKETING", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Locally Advanced or Metastatic Urothelial Carcinoma (UC)" ], "interventions": [ { "name": "enfortumab vedotin (EV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 15, "location_summary": "Los Angeles, California • Santa Monica, California • Santa Rosa, California + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Fort Lauderdale", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04136808" }, { "nct_id": "NCT03582475", "title": "Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Bladder Small Cell Neuroendocrine Carcinoma", "Castration-Resistant Prostate Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Prostate Carcinoma Metastatic in the Bone", "Prostate Neuroendocrine Neoplasm", "Prostate Small Cell Carcinoma", "Stage III Bladder Cancer American Joint Committee on Cancer ( AJCC) v8", "Stage III Prostate Cancer AJCC v8", "Stage III Urethral Cancer AJCC v8", "Stage IV Bladder Cancer AJCC v8", "Stage IV Prostate Cancer AJCC v8", "Stage IV Urethral Cancer AJCC v8", "Stage IVA Bladder Cancer AJCC v8", "Stage IVB Bladder Cancer AJCC v8", "Ureter Small Cell Carcinoma", "Urothelial Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2019-01-11", "completion_date": "2026-12-01", "has_results": true, "last_update_posted_date": "2025-11-12", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03582475" }, { "nct_id": "NCT04637594", "title": "Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Locally Advanced Bladder Urothelial Carcinoma", "Locally Advanced Renal Pelvis Urothelial Carcinoma", "Locally Advanced Ureter Urothelial Carcinoma", "Locally Advanced Urethral Urothelial Carcinoma", "Locally Advanced Urothelial Carcinoma", "Metastatic Bladder Urothelial Carcinoma", "Metastatic Renal Pelvis Urothelial Carcinoma", "Metastatic Ureter Urothelial Carcinoma", "Metastatic Urethral Urothelial Carcinoma", "Metastatic Urothelial Carcinoma" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Nivolumab", "type": "DRUG" }, { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3, "start_date": "2022-05-27", "completion_date": "2030-09", "has_results": true, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 377, "location_summary": "Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 260 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04637594" }, { "nct_id": "NCT02807636", "title": "Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Urothelial Carcinoma" ], "interventions": [ { "name": "Atezolizumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1213, "start_date": "2016-06-30", "completion_date": "2024-02-12", "has_results": true, "last_update_posted_date": "2025-02-24", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 18, "location_summary": "Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more", "locations": [ { "city": "Rogers", "state": "Arkansas" }, { "city": "San Luis Obispo", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Norwalk", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT02807636" }, { "nct_id": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Melanoma", "Renal Cell Carcinoma", "Non Small Cell Lung Cancer", "Urothelial Carcinoma", "Triple Negative Breast Cancer", "HR+/HER2- Breast Cancer", "Gastric Cancer" ], "interventions": [ { "name": "Dose Escalation Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Dose Expansion Doublet: Combination of NKTR-214 + nivolumab", "type": "DRUG" }, { "name": "Schedule Finding Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" }, { "name": "Dose Expansion Triplet: Combination of NKTR-214+ nivolumab+ ipilimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 557, "start_date": "2016-12-19", "completion_date": "2022-04-28", "has_results": true, "last_update_posted_date": "2023-03-13", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 22, "location_summary": "La Jolla, California • Los Angeles, California • Stanford, California + 17 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02983045" }, { "nct_id": "NCT07386847", "title": "A Real-world Study of the First Treatment and Outcomes of Patients With Advanced or Metastatic Bladder Cancer", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Metastatic Urothelial Carcinoma", "Urothelial Cancer", "Urothelial Carcinoma", "Locally Advanced or Metastatic Urothelial Carcinoma" ], "interventions": [], "intervention_types": [], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2026-02-12", "completion_date": "2026-03-30", "has_results": false, "last_update_posted_date": "2026-05-28", "last_synced_at": "2026-10-09T15:01:29.854Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07386847" } ] }